LABELS · 2a999573-102f-813a-e063-6294a90a49b1

Lubiprostone

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-12-31
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of Lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.

Full extracted label fields

application numbers

NDA021908

boxed warning exact

brand names

Lubiprostone

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=031149b9-c709-de1f-e063-6394a90a6d81

generic names

LUBIPROSTONE

2a999573-102f-813a-e063-6294a90a49b1

indications and usage exact

1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of Lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.

indications and usage tables exact

is original packager

manufacturer names

Advanced Rx of Tennessee, LLC

matched search terms

cancer

package ndcs

80425-0355-2

product ndcs

80425-0355

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

616578

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

meta

disclaimer

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

last updated

2026-09-09

license

https://open.fda.gov/license/

results

limit: 100
skip: 100
total: 830

terms

https://open.fda.gov/terms/

sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

url

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl effective time

20241231

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

substance names

LUBIPROSTONE

uniis

7662KG2R6K

verification flags

oncology_keyword_candidate_not_clinically_classified
spl_text_not_verified_identical_to_latest_approved_label
individual_indications_not_split_or_reconciled
not_identified_as_original_packager

Drugs@FDA application source records

application number
NDA021908
payload
all indexed label documents
Appl No
021908
Application Docs Date
2008-05-02 00:00:00
Application Docs ID
16555
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021908s005lbl.pdf
Submission No
5
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2011-03-04 00:00:00
Application Docs ID
16556
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021908s008lbl.pdf
Submission No
8
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2012-11-26 00:00:00
Application Docs ID
16557
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf
Submission No
10
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2013-04-23 00:00:00
Application Docs ID
16558
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021908s011lbl.pdf
Submission No
11
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2006-02-02 00:00:00
Application Docs ID
37863
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021908s000lbl.pdf
Submission No
1
Submission Type
ORIG
Appl No
021908
Application Docs Date
2007-05-29 00:00:00
Application Docs ID
37864
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021908s004lbl.pdf
Submission No
4
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2016-11-01 00:00:00
Application Docs ID
45750
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021908s013lbl.pdf
Submission No
13
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2017-08-02 00:00:00
Application Docs ID
49204
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021908s015lbl.pdf
Submission No
15
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2018-04-27 00:00:00
Application Docs ID
53862
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021908s016lbl.pdf
Submission No
16
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2020-12-04 00:00:00
Application Docs ID
65500
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021908s018lbl.pdf
Submission No
18
Submission Type
SUPPL
all submission records
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
18
Submission Status
AP
Submission Status Date
2020-11-30 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
PRIORITY
Submission Class Code ID
2
Submission No
16
Submission Status
AP
Submission Status Date
2018-04-26 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
15
Submission Status
AP
Submission Status Date
2017-08-01 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
13
Submission Status
AP
Submission Status Date
2016-10-11 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
12
Submission Status
AP
Submission Status Date
2013-08-19 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
PRIORITY
Submission Class Code ID
2
Submission No
11
Submission Status
AP
Submission Status Date
2013-04-19 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
10
Submission Status
AP
Submission Status Date
2012-11-26 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
8
Submission Status
AP
Submission Status Date
2011-02-24 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
UNKNOWN
Submission Class Code ID
2
Submission No
5
Submission Status
AP
Submission Status Date
2008-04-29 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
4
Submission Status
AP
Submission Status Date
2007-05-16 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
7
Submission No
1
Submission Status
AP
Submission Status Date
2006-01-31 00:00:00
Submission Type
ORIG
Submissions Public Notes
application number
NDA021908
approval interpretation
Application linkage and approved submission are not indication-level current approval verification
current indication status
not_reconciled
drugsfda url
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021908
has approved submission record
true
latest approved submission date
2020-11-30
latest label selection rule
max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
latest posted label documents
Appl No
021908
Application Docs Date
2020-12-04 00:00:00
Application Docs ID
65500
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021908s018lbl.pdf
Submission No
18
Submission Type
SUPPL
official application record
Appl No
021908
Appl Public Notes
Appl Type
NDA
Sponsor Name
SUCAMPO PHARMA LLC
openfda application present
true
products
Active Ingredient
LUBIPROSTONE
Appl No
021908
Drug Name
AMITIZA
Form
CAPSULE;ORAL
Product No
001
Reference Drug
1
Reference Standard
1
Strength
24MCG
marketing status
Prescription
Active Ingredient
LUBIPROSTONE
Appl No
021908
Drug Name
AMITIZA
Form
CAPSULE;ORAL
Product No
002
Reference Drug
1
Reference Standard
0
Strength
8MCG
marketing status
Prescription

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 349
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 0

current approval status

not_reconciled

duplicate text group

dup-f9adb1af433caebca9df

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-b3f9256c412a497d5e7f

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

end: 78
end exclusive: true
exact text: is a chloride channel activator indicated
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 37

qualifier mentions

context exact
the treatment of: chronic idiopathic constipation (CIC) in adults.
kind
age
polarity
not_inferred
span
end
148
end exclusive
true
exact text
adults
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
142

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 149
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 587
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 0

current approval status

not_reconciled

duplicate text group

dup-601d9a16d76253203035

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-2818eb7c4d44c2316991

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

end: 78
end exclusive: true
exact text: is a chloride channel activator indicated
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 37

qualifier mentions

context exact
( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chro
kind
age
polarity
not_inferred
span
end
209
end exclusive
true
exact text
adult patients
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
195

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 387
end exclusive: true
exact text: ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 150

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · limitation of use

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 756
end exclusive: true
exact text: IC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 188

current approval status

not_reconciled

duplicate text group

dup-069d3fdec4aed80f4294

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-d3e5e673873466786df4

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

Source null

qualifier mentions

context exact
nt of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established.
kind
biomarker
polarity
not_inferred
span
end
555
end exclusive
true
exact text
methadone) has not been established
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
520

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 556
end exclusive: true
exact text: ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 388

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · unclassified context

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 846
end exclusive: true
exact text: kly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 357

current approval status

not_reconciled

duplicate text group

dup-52769a4de0ff665b3cd7

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-fc1bf0a7f097eb76f773

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

Source null

qualifier mentions

context exact
ritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old.
kind
age
polarity
not_inferred
span
end
641
end exclusive
true
exact text
18 years
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
633

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 646
end exclusive: true
exact text: ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 557

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 854
end exclusive: true
exact text: n the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Ch
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 447

current approval status

not_reconciled

duplicate text group

dup-0638dc434ec6f0b76eb5

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-aba0f8217785bc778f6d

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 654
end exclusive: true
exact text: ( 1.3 )
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 647

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 996
end exclusive: true
exact text: eatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-canc
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 455

current approval status

not_reconciled

duplicate text group

dup-0ae31775534330e51a9d

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-fb7ee02313bfe03ecdf2

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

end: 726
end exclusive: true
exact text: is indicated
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 714

qualifier mentions

context exact
1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idio
kind
age
polarity
not_inferred
span
end
700
end exclusive
true
exact text
Adults
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
694
context exact
r the treatment of chronic idiopathic constipation (CIC) in adults.
kind
age
polarity
not_inferred
span
end
795
end exclusive
true
exact text
adults
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
789

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 796
end exclusive: true
exact text: 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 655

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1351
end exclusive: true
exact text: ith constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of Lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 597

current approval status

not_reconciled

duplicate text group

dup-b31e03670173eea2a32a

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-cd6192aa9fa7560b21f9

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

end: 901
end exclusive: true
exact text: is indicated
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 889

qualifier mentions

context exact
1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for
kind
age
polarity
not_inferred
span
end
846
end exclusive
true
exact text
Adult Patients
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
832
context exact
d for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chron
kind
age
polarity
not_inferred
span
end
974
end exclusive
true
exact text
adult patients
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
960

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1151
end exclusive: true
exact text: 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 797

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 8 · limitation of use

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1544
end exclusive: true
exact text: OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of Lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 952

current approval status

not_reconciled

duplicate text group

dup-8f7fbc38619a7603e3b2

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-a1a53b39e1bb1584cc6a

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

Source null

qualifier mentions

context exact
stipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ]
kind
biomarker
polarity
not_inferred
span
end
1335
end exclusive
true
exact text
methadone) has not been established
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
1300

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1367
end exclusive: true
exact text: Limitations of Use: Effectiveness of Lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ]
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 1152

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 9 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1544
end exclusive: true
exact text: se: Effectiveness of Lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 1168

current approval status

not_reconciled

duplicate text group

dup-9f6b252fe888db4851bc

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-d56e0ccb80d15444272a

label id

2a999573-102f-813a-e063-6294a90a49b1

positive predicate support span

end: 1440
end exclusive: true
exact text: is indicated
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 1428

qualifier mentions

context exact
bowel syndrome with constipation (IBS-C) in women at least 18 years old.
kind
age
polarity
not_inferred
span
end
1539
end exclusive
true
exact text
18 years
label id
2a999573-102f-813a-e063-6294a90a49b1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start
1531

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1544
end exclusive: true
exact text: 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.
label id: 2a999573-102f-813a-e063-6294a90a49b1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d9f430df144aaec9bee3b5d418a9be968424b1363a4bd1c41394d9e8006a3442
start: 1368

source url

https://api.fda.gov/drug/label.json?search=id%3A%222a999573-102f-813a-e063-6294a90a49b1%22

spl effective date

2024-12-31

spl set id

031149b9-c709-de1f-e063-6394a90a6d81

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice